文献速递免疫规划传染病防控与疫情报告

针对Y280谱系H9N2现场病毒的重组疫苗候选株开发及其保护效力

Development of a recombinant H9N2 influenza vaccine candidate against the Y280 lineage field virus and its protective efficacy.
PubMed 文献 · Vaccine · 2021-09-14

韩国自2020年6月起流行Y280谱系新型H9N2病毒,研究评估了针对Y280和Y439谱系的韩国商业疫苗及重组候选株rgHS314在SPF鸡中的免疫原性与保护效果。单次接种商业疫苗不能保护鸡抵抗Y280谱系病毒,而rgHS314单次接种可诱导交叉反应免疫,显著减少病毒排毒并对同源和异源攻击病毒分别实现100%和83.3%的盲肠扁桃体病毒回收抑制。

要点

  • 商业H9N2疫苗单次接种对Y280谱系病毒无显著保护,病毒回收抑制仅37.5%。
  • 重组候选株rgHS314在SPF鸡中具免疫原性且鸡胚产量高。
  • rgHS314单次接种对同源和异源攻击的病毒回收抑制分别为100%和83.3%。

核心结论

  • 重组疫苗候选株rgHS314单次接种可诱导交叉反应免疫,保护鸡抵抗Y439和Y280谱系H9N2病毒。

研究设计与样本

  • 在SPF鸡中评估韩国商业H9N2疫苗(针对Y280和Y439谱系)及重组候选株rgHS314的免疫原性与保护效力。

主要发现

  • 商业疫苗单次接种未保护鸡抵抗Y280谱系病毒,病毒排毒无显著减少,盲肠扁桃体病毒回收抑制率为37.5%。
  • rgHS314在SPF鸡中显示免疫原性,且在鸡胚中产量高。
  • rgHS314单次接种对同源和异源攻击病毒分别实现100%和83.3%的盲肠扁桃体病毒回收抑制,并显著减少病毒排毒。

关键数值与推荐

  • 商业疫苗单次接种对Y280谱系病毒的盲肠扁桃体病毒回收抑制率为37.5%。
  • rgHS314单次接种对同源攻击病毒的盲肠扁桃体病毒回收抑制率为100%,对异源攻击病毒为83.3%。

临床怎么用

  • 针对Y280谱系H9N2流行,可考虑使用重组候选株rgHS314进行单次接种以诱导交叉保护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Since June 2020, a new H9N2 virus of the Y280 lineage has been epidemic in Korea. Initially, a Korean commercial vaccine against the Y280 and Y439 lineages of H9N2 was evaluated for use in SPF chickens. A single vaccination did not protect chickens against virus of the Y280 lineage, with no significant reduction in virus shedding and a 37.5% inhibition in virus recovery rate in cecal tonsil. rgHS314 was selected as a vaccine candidate, showing immunogenicity in SPF chickens, and was highly productive in eggs. Moreover, rgHS314 protected with high levels of protective immunity and significantly reduced virus shedding, with 100% and 83.3% inhibition of virus recovery in the cecal tonsil against homologous and heterologous challenge viruses, respectively. Taken together, these data suggest that a single vaccination with this recombinant vaccine candidate could elicit cross-reactive immune responses capable of protecting chickens against H9N2 viruses of the Y439 and Y280 lineages.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kim DY, Kang YM, Cho HK, et al. Development of a recombinant H9N2 influenza vaccine candidate against the Y280 lineage field virus and its protective efficacy. Vaccine. 2021. PMID: 34535319. doi:10.1016/j.vaccine.2021.08.089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。